219 related articles for article (PubMed ID: 11999555)
1. Apoptosis and prognostic factors in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Leuk Lymphoma; 2002 Feb; 43(2):257-60. PubMed ID: 11999555
[TBL] [Abstract][Full Text] [Related]
2. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
4. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
5. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
6. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment.
Bogdanović AD; Trpinac DP; Janković GM; Bumbasirević VZ; Obradović M; Colović MD
Leukemia; 1997 May; 11(5):656-9. PubMed ID: 9180288
[TBL] [Abstract][Full Text] [Related]
7. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
8. [Myelodysplastic syndrome: a review].
Creutzig U; Hoelzer D
Klin Padiatr; 1987; 199(3):169-72. PubMed ID: 3626418
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
10. In vitro growth modulation by L-ascorbic acid of colony-forming cells from bone marrow of patients with myelodysplastic syndromes.
Park CH; Kimler BF; Bodensteiner D; Lynch SR; Hassanein RS
Cancer Res; 1992 Aug; 52(16):4458-66. PubMed ID: 1643638
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
12. [Contemporary possibilities of prognosis in myelodysplastic syndromes].
Goździk J; Lewandowski K; Hansz J
Acta Haematol Pol; 1995; 26(2):129-38. PubMed ID: 7653217
[TBL] [Abstract][Full Text] [Related]
13. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes.
Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
Int J Hematol; 1993 Aug; 58(1-2):53-61. PubMed ID: 8219112
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
15. I walk the line: how to tell MDS from other bone marrow failure conditions.
Gondek LP; DeZern AE
Curr Hematol Malig Rep; 2014 Dec; 9(4):389-99. PubMed ID: 25079655
[TBL] [Abstract][Full Text] [Related]
16. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
Schemenau J; Baldus S; Anlauf M; Reinecke P; Braunstein S; Blum S; Nachtkamp K; Neukirchen J; Strup C; Aul C; Haas R; Gattermann N; Germing U
Eur J Haematol; 2015 Sep; 95(3):181-9. PubMed ID: 25600827
[TBL] [Abstract][Full Text] [Related]
17. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
[TBL] [Abstract][Full Text] [Related]
18. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
19. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
20. [Advances of study on immunophenotyping of myelodysplastic syndromes-review].
Qiao C; Fan L; Wu YJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1106-10. PubMed ID: 19698271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]